462 related articles for article (PubMed ID: 11263296)
1. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
3. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
4. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
Tan Y; Zhang P; Zheng C
Zhonghua Zhong Liu Za Zhi; 1999 Jul; 21(4):287-9. PubMed ID: 11776818
[TBL] [Abstract][Full Text] [Related]
6. [The value of serum tumor marker in the diagnosis of lung cancer].
Shi GL; Hu XL; Yue SD; Song CX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
[TBL] [Abstract][Full Text] [Related]
7. [Detection of serum CK19-2G2 and Cyfra21-1 protein and comparison of their diagnostic value for lung cancer].
Gao J; Wang H; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):930-2. PubMed ID: 19173996
[TBL] [Abstract][Full Text] [Related]
8. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
9. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S
Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666
[TBL] [Abstract][Full Text] [Related]
11. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
[TBL] [Abstract][Full Text] [Related]
13. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis.
Takahashi H; Kurishima K; Ishikawa H; Kagohashi K; Kawaguchi M; Satoh H
Anticancer Res; 2010 Sep; 30(9):3833-7. PubMed ID: 20944179
[TBL] [Abstract][Full Text] [Related]
14. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
15. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
16. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
[TBL] [Abstract][Full Text] [Related]
17. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
Ebert W; Muley T
Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
[TBL] [Abstract][Full Text] [Related]
18. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer.
Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H
Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]